Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Bioconjug Chem ; 31(4): 1199-1208, 2020 04 15.
Article En | MEDLINE | ID: mdl-32178516

Antibody-drug conjugates (ADCs) are a therapeutic modality that traditionally enable the targeted delivery of highly potent cytotoxic agents to specific cells such as tumor cells. More recently, antibodies have been used to deliver molecules such as antibiotics, antigens, and adjuvants to bacteria or specific immune cell subsets. Site-directed mutagenesis of proteins permits more precise control over the site and stoichiometry of their conjugation, giving rise to homogeneous chemically defined ADCs. Identification of favorable sites for conjugation in antibodies is essential as reaction efficiency and product stability are influenced by the tertiary structure of immunoglobulin G (IgG). Current methods to evaluate potential conjugation sites are time-consuming and labor intensive, involving multistep processes for individually produced reactions. Here, we describe a highly efficient method for identification of conjugatable genetic variants by analyzing pooled ADC libraries using mass spectrometry. This approach provides a versatile platform to rapidly uncover new conjugation sites for site-specific ADCs.


Immunoconjugates/chemistry , Immunoconjugates/genetics , Genetic Variation , Immunoglobulin G/chemistry , Mass Spectrometry , Protein Structure, Tertiary
2.
J Am Chem Soc ; 139(32): 11089-11095, 2017 08 16.
Article En | MEDLINE | ID: mdl-28719738

Control of enzyme activity is fundamental to biology and represents a long-term goal in bioengineering and precision therapeutics. While several powerful molecular strategies have been developed, limitations remain in their generalizability and dynamic range. We demonstrate a control mechanism via separate small molecules that turn on the enzyme (activator) and turn off the activation (blocker). We show that a pocket created near the active site base of the enzyme ketosteriod isomerase (KSI) allows efficient and saturable base rescue when the enzyme's natural general base is removed. Binding a small molecule with similar properties but lacking general-base capability in this pocket shuts off rescue. The ability of small molecules to directly participate in and directly block catalysis may afford a broad controllable dynamic range. This approach may be amenable to numerous enzymes and to engineering and screening approaches to identify activators and blockers with strong, specific binding for engineering and therapeutic applications.


Catalytic Domain/drug effects , Comamonas testosteroni/enzymology , Pseudomonas putida/enzymology , Small Molecule Libraries/pharmacology , Steroid Isomerases/metabolism , Binding Sites/drug effects , Comamonas testosteroni/chemistry , Comamonas testosteroni/drug effects , Comamonas testosteroni/genetics , Enzyme Activation/drug effects , Models, Molecular , Mutagenesis, Site-Directed , Mutation , Pseudomonas putida/chemistry , Pseudomonas putida/drug effects , Pseudomonas putida/genetics , Small Molecule Libraries/chemistry , Steroid Isomerases/chemistry , Steroid Isomerases/genetics
3.
Biochemistry ; 56(4): 582-591, 2017 01 31.
Article En | MEDLINE | ID: mdl-28045505

Kemp eliminases represent the most successful class of computationally designed enzymes, with rate accelerations of up to 109-fold relative to the rate of the same reaction in aqueous solution. Nevertheless, several other systems such as micelles, catalytic antibodies, and cavitands are known to accelerate the Kemp elimination by several orders of magnitude. We found that the naturally occurring enzyme ketosteroid isomerase (KSI) also catalyzes the Kemp elimination. Surprisingly, mutations of D38, the residue that acts as a general base for its natural substrate, produced variants that catalyze the Kemp elimination up to 7000-fold better than wild-type KSI does, and some of these variants accelerate the Kemp elimination more than the computationally designed Kemp eliminases. Analysis of the D38N general base KSI variant suggests that a different active site carboxylate residue, D99, performs the proton abstraction. Docking simulations and analysis of inhibition by active site binders suggest that the Kemp elimination takes place in the active site of KSI and that KSI uses the same catalytic strategies of the computationally designed enzymes. In agreement with prior observations, our results strengthen the conclusion that significant rate accelerations of the Kemp elimination can be achieved with very few, nonspecific interactions with the substrate if a suitable catalytic base is present in a hydrophobic environment. Computational design can fulfill these requirements, and the design of more complex and precise environments represents the next level of challenges for protein design.


Bacterial Proteins/chemistry , Comamonas testosteroni/chemistry , Intramolecular Lyases/chemistry , Ketosteroids/chemistry , Oxazoles/chemistry , Protons , Steroid Isomerases/chemistry , Arginine/chemistry , Arginine/metabolism , Aspartic Acid/chemistry , Aspartic Acid/metabolism , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biocatalysis , Cloning, Molecular , Comamonas testosteroni/enzymology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Escherichia coli/genetics , Escherichia coli/metabolism , Gene Expression , Hydrophobic and Hydrophilic Interactions , Intramolecular Lyases/antagonists & inhibitors , Intramolecular Lyases/genetics , Intramolecular Lyases/metabolism , Ketosteroids/metabolism , Kinetics , Molecular Docking Simulation , Mutation , Oxazoles/metabolism , Protein Engineering , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Steroid Isomerases/antagonists & inhibitors , Steroid Isomerases/genetics , Steroid Isomerases/metabolism , Structure-Activity Relationship
4.
J Am Chem Soc ; 138(31): 9902-9, 2016 08 10.
Article En | MEDLINE | ID: mdl-27410422

Proton transfer reactions are ubiquitous in enzymes and utilize active site residues as general acids and bases. Crystal structures and site-directed mutagenesis are routinely used to identify these residues, but assessment of their catalytic contribution remains a major challenge. In principle, effective molarity measurements, in which exogenous acids/bases rescue the reaction in mutants lacking these residues, can estimate these catalytic contributions. However, these exogenous moieties can be restricted in reactivity by steric hindrance or enhanced by binding interactions with nearby residues, thereby resulting in over- or underestimation of the catalytic contribution, respectively. With these challenges in mind, we investigated the catalytic contribution of an aspartate general base in ketosteroid isomerase (KSI) by exogenous rescue. In addition to removing the general base, we systematically mutated nearby residues and probed each mutant with a series of carboxylate bases of similar pKa but varying size. Our results underscore the need for extensive and multifaceted variation to assess and minimize steric and positioning effects and determine effective molarities that estimate catalytic contributions. We obtained consensus effective molarities of ∼5 × 10(4) M for KSI from Comamonas testosteroni (tKSI) and ∼10(3) M for KSI from Pseudomonas putida (pKSI). An X-ray crystal structure of a tKSI general base mutant showed no additional structural rearrangements, and double mutant cycles revealed similar contributions from an oxyanion hole mutation in the wild-type and base-rescued reactions, providing no indication of mutational effects extending beyond the general base site. Thus, the high effective molarities suggest a large catalytic contribution associated with the general base. A significant portion of this effect presumably arises from positioning of the base, but its large magnitude suggests the involvement of additional catalytic mechanisms as well.


Ketosteroids/chemistry , Steroid Isomerases/chemistry , Aspartic Acid/chemistry , Binding Sites , Carbon/chemistry , Catalysis , Catalytic Domain , Comamonas testosteroni/enzymology , Crystallography, X-Ray , Hydrogen Bonding , Hydrogen-Ion Concentration , Isomerases/metabolism , Kinetics , Mutagenesis, Site-Directed , Mutation , Pseudomonas putida/enzymology
5.
Science ; 349(6251): 936, 2015 Aug 28.
Article En | MEDLINE | ID: mdl-26315426

Fried et al. (Reports, 19 December 2014, p. 1510) demonstrated a strong correlation between reaction rate and the carbonyl stretching frequency of a product analog bound to ketosteroid isomerase oxyanion hole mutants and concluded that the active-site electric field provides 70% of catalysis. Alternative comparisons suggest a smaller contribution, relative to the corresponding solution reaction, and highlight the importance of atomic-level descriptions.


Ketosteroids/metabolism , Static Electricity , Steroid Isomerases/chemistry
6.
Curr Pharm Des ; 18(20): 2936-45, 2012.
Article En | MEDLINE | ID: mdl-22571662

Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.


Drug Delivery Systems , Protein Kinase Inhibitors/pharmacology , Protein Kinases/drug effects , Adenosine Triphosphate/metabolism , Allosteric Regulation , Binding Sites , Drug Design , Humans , Protein Binding , Protein Kinase Inhibitors/adverse effects , Protein Kinases/metabolism
...